A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
Part of paid clinical trials in Peoria, Arizona.
- Sponsor
- Hoffmann-La Roche
- Study ID
- NCT07137598
- Phase
- PHASE2
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Afimkibart — DRUGAfimkibart will be administered as SC injection.
- Placebo — DRUGPlacebo will be administered as SC injection.
Study Details
This study will assess the efficacy and safety of Afimkibart (also known as RO7790121) compared with placebo in participants with moderate to severe rheumatoid arthritis (RA) who have an inadequate response or intolerance to TNF and/or JAK inhibitors.
Key Dates
- Start date
- Dec 5, 2025
- Status verified
- May 2026
- Primary completion
- Apr 19, 2027
- Completion
- Oct 8, 2027
Study Design
- Enrollment
- 160 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Afimkibart Group IParticipants will receive afimkibart via subcutaneous (SC) injection.
- Experimental: Afimkibart Group IIParticipants will receive afimkibart via SC injection.
- Placebo Comparator: PlaceboParticipants will receive afimkibart matched placebo via SC injection.
Primary Outcome Measure
Change from Baseline in Disease Activity Score-28 for Rheumatoid Arthritis with C-Reactive Protein (DAS28-CRP) [ Time Frame: Baseline, At Week 14 ]
Central Contacts
- Reference Study ID Number: WA45846 https://forpatients.roche.com/888-662-6728 (U.S. and Canada)
- Fastest response: use the inquiry form. No email attachments. https://www.gene.com/contact-us/submit-medical-inquiry
Locations (12)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| SunValley Arthritis Center Ltd. | Peoria | Arizona | 85381 | - |
| Cedars Sinai Medical Center | Los Angeles | California | 90048 | - |
| Inland Rheumatology Clinical Trials Incorporated | Upland | California | 91786 | - |
| West Broward Rheumatology Associates, Inc. | Tamarac | Florida | 33321 | - |
| Willow Rheumatology and Wellness PLLC | Willowbrook | Illinois | 60527 | - |
| Accurate Clinical Research Inc. | Lake Charles | Louisiana | 70605 | - |
| Ohio State University Wexner Medical Center | Columbus | Ohio | 43203 | - |
| Altoona Center For Clinical Research | Duncansville | Pennsylvania | 16635 | - |
| Accurate Clinical Management | Houston | Texas | 77089 | - |
| DM Clinical Research | Tomball | Texas | 77375 | - |
| Tidewater Clinical Research | Chesapeake | Virginia | 23320 | - |
| Rheumatic Disease Center | Glendale | Wisconsin | 53217 | - |
Find similar trials in Peoria, AZ
By condition
By research site
SunValley Arthritis Center Ltd.· Peoria, AZCedars Sinai Medical Center· Los Angeles, CAInland Rheumatology Clinical Trials Incorporated· Upland, CAWest Broward Rheumatology Associates, Inc.· Tamarac, FLWillow Rheumatology and Wellness PLLC· Willowbrook, ILAccurate Clinical Research Inc.· Lake Charles, LA
Related Studies
- Physica System Total Knee Replacement Registry StudyRecruiting · Limacorporate S.p.a · Rancho Mirage, California
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPHASE1 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- RA-PRO PRAGMATIC TRIALPHASE3 · Recruiting · University of Alabama at Birmingham · Auburn, Alabama
- Effect of Anti-inflammatory Diet in Rheumatoid ArthritisRecruiting · University of California, San Diego · La Jolla, California